Primary lung cancer
Conditions
Interventions
Experimental group:Aipalolitoworilimab combined with docetaxel
Sponsors
Henan Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75, no gender restriction; 2. Metastatic non-small cell lung cancer confirmed by pathological histology or cytology, with negative results for driver gene testing after genetic testing; 3. Previously failed combined chemotherapy and immunotherapy; 4. According to the Response Evaluation Criteria In Solid Tumors (RECIST 1.1), there must be at least one measurable lesion. 5. ECOG score 0-2; 6. Expected survival period >= 12 weeks. 7. All observed patients have voluntarily signed the informed consent for experimental treatment and can understand and comply with the study requirements to complete the research.
Exclusion criteria
Exclusion criteria: 1. Has a history of drug allergies; 2. Previous bispecific antibody therapy; 3. Active leptomeningeal metastases, brain metastases, or spinal cord compression. Unless the patient's disease is stable (asymptomatic; no evidence of new or progressive brain metastases), corticosteroid therapy must be discontinued for at least 14 days prior to the start of treatment. For patients with brain metastases who have received radiation therapy and/or surgery, a waiting period of 28 days after the intervention is required, and disease stability must be confirmed by imaging assessment prior to enrollment. 4. Has had other malignant tumors in the past 5 years, except for those that have been cured; 5. Has a history of immunodeficiency, or suffers from other acquired or congenital immunodeficiency diseases, or has a history of organ transplantation; 6. Combine history of myocardial infarction, history of heart failure, and active infection; 7. Pregnant, pre-pregnant, and lactating women; 8. Researchers evaluate patients with poor compliance who cannot guarantee treatment and follow-up according to the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective Response Rate;Overall Survival;Disease Control Rate,DCR; | — |
Countries
China
Contacts
Public ContactTang Hong
Henan Cancer Hospital
Outcome results
None listed